Publications by authors named "Matthias Stelljes"

Claim this Profile
I
Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party.
Agnieszka Piekarska, Mouad Abouqateb, William Boreland, Christophe Peczynski, Jan Maciej Zaucha, Matthias Stelljes

Bone Marrow Transplant· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Posttransplant cyclophosphamide versus antithymocyte globulin in patients with cardiovascular comorbidity undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukaemia in first complete remission from unrelated donors: a retrospective matched-pair analysis from the ALWP of the EBMT.
Jan Vydra, Allain-Thibeault Ferhat, Nicolaus Kröger, Tobias Gedde-Dahl, Matthias Eder, Matthias Stelljes

Bone Marrow Transplant· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced intensity conditioning with 8 Gy total body irradiation in adult patients with acute lymphoblastic leukemia.
Klaus Wethmar, Matthias Edinger, Kerstin Schäfer-Eckart, Matthias Stelljes, Thomas Schroeder

Bone Marrow Transplant· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of people living with acute lymphoblastic leukemia who received inotuzumab ozogamicin before a stem cell transplant: a plain language summary.
Marcos de Lima, Partow Kebriaei, Francesco Lanza, Christina Cho, Gizelle Popradi, Matthias Stelljes

Future Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.
Anne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, Katja Sockel, Rebekka Wehner, Matthias Stelljes

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pretransplant HMA and Venetoclax in AML patients - a Real-World Analysis from the Cooperative Transplant Study Group.
Christina Rautenberg, Matthias Stelljes, Gesine Bug, Udo Holtick, Edgar Jost

Transplant Cell Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva-Maria Wagner-Drouet, Lutz P Müller

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune reconstitution in AML and MDS patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with treosulfan- or TBI-based conditioning.
Lina Kolloch, Philipp Berning, Jörn C Albring, Julian Ronnacker, Christian Reicherts, Matthias Stelljes

Bone Marrow Transplant· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMT.
Kordelia Barbullushi, Myriam Labopin, Nicolaus Kröger, Jürgen Finke, Matthias Stelljes

Bone Marrow Transplant· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of donor selection in adverse-risk AML undergoing hematopoietic cell transplantation: A study from the EBMT Acute Leukemia Working Party.
Marta Villalba, Allain-Thibeault Ferhat, Tobias Gedde-Dahl, Gerard Socie, Anne Huynh, Matthias Stelljes

Bone Marrow Transplant· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Dose Melphalan Followed by Busulfan and Fludarabine Conditioning Prior to Allogeneic Stem Cell Transplantation in Elderly Patients with Active Acute Myeloid Leukemia-A Retrospective Single-Center Study.
Julian Ronnacker, Marc-Andre Urbahn, Christian Reicherts, Simon Call, Eva Eßeling, Matthias Stelljes

Transplant Cell Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.
Mark J Levis, Mehdi Hamadani, Brent R Logan, Richard J Jones, Anurag K Singh, Matthias Stelljes

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT.
Simona Iacobelli, Stefan Schönland, Linda Koster, Didier Blaise, Emma Nicholson, Matthias Stelljes

Bone Marrow Transplant· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings.
Johannes Schetelig, Henning Baldauf, Carina Rave, Gesine Bug, Lutz P Müller, Matthias Stelljes

Leukemia· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treosulfan-Based Conditioning Ameliorates the Impact of Pretransplantation Measurable Residual Disease-Positivity in Acute Myeloid Leukemia Patients Allografted in Remission.
Jacob Pyka, Judith Metzdorf, Christian Reicherts, Julia Marx, Nils Leimkühler, Matthias Stelljes

Transplant Cell Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.
Patryk Sobieralski, Tomasz Czerw, Luuk Gras, Linda Koster, Nicolaus Kröger, Matthias Stelljes

Bone Marrow Transplant· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic significance of cytogenetic risk score in patients with secondary acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-matched unrelated donors: a study from the ALWP /EBMT.
Arnon Nagler, Allain-Thibeault Ferhat, Sarah Kayser, Matthias Eder, Nicolaus Kröger, Matthias Stelljes

Bone Marrow Transplant· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment.
Julian Ronnacker, Leo Ruhnke, Christoph Röllig, Jan Moritz Middeke, Regina Herbst, Matthias Stelljes

Leukemia· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis.
Markus Maulhardt, Simon Call, Hristo Boyadzhiev, Anca Maria Albici, Keven Hörster, Matthias Stelljes

Hemasphere· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in active disease: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Sara Tarantino, Myriam Labopin, Robert Zeiser, Matthias Stelljes, Thomas Schroeder

Bone Marrow Transplant· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CXCL16/CXCR6 axis is linked to immune effector cell-associated neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
I-Na Lu, Louisa Müller-Miny, Carolin Krekeler, Phyllis Fung-Yi Cheung, Georgia Antonopoulou, Matthias Stelljes

Genome Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of Patients With IDH-Mutated AML Following Allogeneic Stem Cell Transplantation-A Retrospective Analysis on Behalf of the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy, DRST.
Thomas Schroeder, Sarah Flossdorf, Claudia Schuh, Caroline Pabst, Michael Stadler, Matthias Stelljes

Transplant Cell Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying people with acute lymphoblastic leukemia who are most suitable for treatment with inotuzumab ozogamicin: a plain language summary.
David I Marks, Ryan D Cassaday, Josep-Maria Ribera, Andre C Schuh, Jae H Park, Matthias Stelljes

Expert Rev Hematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition.
Anna Ossami Saidy, Christophe Peczynski, Catherine Thieblemont, Michael Daskalakis, Marc Wehrli, Matthias Stelljes

Hemasphere· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia - long-term follow-up with focus on younger patients.
Christina Rautenberg, Jan Moritz Middeke, Christoph Röllig, Matthias Stelljes, Verena Gaidzik

Blood Cancer J· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis